ALZ-507 / Alzheon - LARVOL DELTA

Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Alzheon Inc.

New P1 trial

Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism (Businesswire) - "ALZ-507 IND Program Demonstrated Favorable Nonclinical Safety and Pharmacokinetic Profile that Supports Once-Daily Dosing...The Phase 1 clinical trial will assess the safety, tolerability, and pharmacokinetics of both single and multiple ascending doses of ALZ-507. Findings from this investigation are anticipated to guide dose selection and inform formulation strategy for subsequent Phase 2 studies involving patients diagnosed with Alzheimer’s disease (AD), Down syndrome–associated AD, and cerebral amyloid angiopathy (CAA)."

Preclinical • Trial status • Alzheimer's Disease